

### REMARKS

Applicants have carefully considered this Application in connection with the Examiner's Office Action, and respectfully request reconsideration of this Application in view of the above amendments and the following remarks.

Claims 1-24 are pending in this application. Claims 1-3, 5-10, 15-20, and 22-23, have been withdrawn as being drawn to non-elected subject matter.

Claims 4, 13, and 21 have been cancelled.

Claims 11, 12, 14, and 24 are under examination.

#### **I. CLAIM REJECTIONS UNDER 35 USC §112**

The Examiner has rejected Claims 4, 11-12, 14, 21, and 24, under 35 U.S.C. §112, second paragraph, as being indefinite.

The Examiner has stated that the claim term "serotonin reuptake inhibitor" is unclear in Claims 4, 11-12, 14, 21, and 24. Claims 4 and 21 have been cancelled. Applicants have amended Claims 11-12, 14, and 24, to recite "a compound" in the preamble.

The Examiner has stated that Claim 4 is unclear due to the term "aryl moiety." Claim 4 has been cancelled.

The Examiner has stated that Claim 4 recites "exclusionary" provisos. Claim 4 has been cancelled.

#### **II. CLAIM REJECTIONS UNDER 35 USC §102**

A. The Examiner has rejected Claims 4 and 21 under 35 U.S.C. 102(b) as being anticipated by Borowsky, et al., U.S. Patent No. 6,221,613. Applicants note that U.S. Patent No. 6,221,613 does not have first-named inventor "Borowsky." Moreover, the structures cited by the Examiner in the Office Action mailed May 19, 2010, do not appear to be present in U.S. Patent No. 6,221,613.

Claims 4 and 21 have been cancelled, rendering the rejection moot.

### III. CLAIM REJECTIONS UNDER 35 USC §103

A. The Examiner has rejected Claims 4 and 21 under U.S.C. 103(a) as being unpatentable over Martinez-Esparza, et al., *Journal of Medicinal Chemistry* 44(3), 418-428 (2001). Claims 4 and 21 have been cancelled, rendering the rejections moot.

B. The Examiner has rejected Claims 4 and 21 under U.S.C. 103(a) as being unpatentable over Jakobsen et al., EP 576766. Claims 4 and 21 have been cancelled, rendering the rejections moot.


C. The Examiner has rejected Claims 4 and 21 under U.S.C. 103(a) as being unpatentable over Dorsey et al. *Bioorganic & Medicinal Chemistry* 12:1483-91, 2004. Claims 4 and 21 have been cancelled, rendering the rejections moot.

#### IV. Conclusion

Applicants respectfully submit that, in light of the foregoing comments and amendments, all pending claims are now in condition for allowance. A Notice of Allowance is therefore requested.


If the Examiner has any other matters which pertain to this Application, the Examiner is encouraged to contact the undersigned to resolve these matters by Examiner's Amendment where possible.

Respectfully submitted,



---

T. Ling Chwang  
Reg. No. 33,590  
Jackson Walker L.L.P.  
901 Main Street, Suite 6000  
Dallas, Texas 75202  
Tel: (214) 953-5959  
Fax: (214) 661-6870



---

Date